Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy–Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial

Tsumura, Hideyasu; Satoh, Takefumi; Ishiyama, Hiromichi; Tabata, Ken‐ichi; Kotani, Shouko; Minamida, Satoru; Kimura, Masaki; Fujita, Tetsuo; Matsumoto, Kazumasa; Kitano, Masashi; Hayakawa, Kazushige; Baba, Shirō

doi:10.1016/j.ijrobp.2011.04.026

Cited by 41 publications

(29 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, alpha‐blockers have been reported to improve IPSS scores after radiotherapy: Tsumura et al. found that urinary symptoms after brachytherapy in 212 patients improved with use of alpha‐blockers, regardless of type (silodosin, naftopidil, or tamsulosin). Previously, Zelefsky et al.…”

Section: Management Of Lutsmentioning

confidence: 98%

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment

et al. 2015

View full text Add to dashboard Cite

There are various forms of treatment for prostate cancer. In addition to oncologic outcomes, physicians, and increasingly patients, are focusing on functional and adverse outcomes. Symptoms of overactive bladder (OAB), including urinary frequency, urgency and incontinence, can occur regardless of treatment modality. This article examines the prevalence, pathophysiology and options for treating OAB after radical prostate cancer treatment. OAB seems to be more common and severe after radiation therapy than after surgical therapy and even persisted longer with complications, suggesting an advantage for surgery over radiotherapy. Because OAB that occurs after radical prostate surgery or radiotherapy can be difficult to treat, it is important that patients are made aware of the potential development of OAB during counselling before decisions regarding treatment choice are made. To ensure a successful outcome of both treatments, it is imperative that clinicians and non-specialists enquire about and document pretreatment urinary symptoms and carefully evaluate post-treatment symptoms.

show abstract

Section: Management Of Lutsmentioning

confidence: 98%

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…They also revealed that there was not a significant improvement in the bladder outlet obstruction index based on a pressure flow study in the silodosin group. Tsumura et al (12) demonstrated that patients who took silodosin had favorable outcomes for IPSS change compared with the naftopidil and tamsulosin groups in a randomized controlled trial. Overall, the use of an alpha-1 adrenoreceptor antagonist improved the urinary morbidity after seed implantation, but its effect was not adequate in any studies.…”

Section: Phase 3 Trials To Reduce Urinary Toxicitymentioning

confidence: 99%

Urethral toxicity after LDR brachytherapy: Experience in Japan

et al. 2015

View full text Add to dashboard Cite

“…Silodosin showed a significant improvement in the postvoid residual at 6 months vs. tamsulosin. The authors concluded that silodosin has a greater impact on improving LUTS after BT than tamsulosin or naftopidil 97. Oyama et al.…”

Section: Discussionmentioning

confidence: 99%

“…Alpha blockers can be used to treat LUTS such as urge UI or OAB as they relax smooth muscles (112). Tsumura et al compared the efficacy of tamsulosin, silodosin and naftopidil in treating LUTS after BT (97). In this study, 212 patients received one of three alpha 1-adrenoceptor antagonists for 1 year after BT.…”

Section: Alpha Blockersmentioning

confidence: 99%

Integrative review on the non‐invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies

et al. 2015

View full text Add to dashboard Cite

SummaryAimTo develop a non‐invasive management strategy for men with lower urinary tract symptoms (LUTS) after treatment for pelvic cancer, that is suitable for use in a primary healthcare context.MethodsPubMed literature searches of LUTS management in this patient group were carried out, together with obtaining a consensus of management strategies from a panel of authors for the management of LUTS from across the UK.ResultsData from 41 articles were investigated and collated. Clinical experience was sought from authors where there was no clinical evidence. The findings discussed in this paper confirm that LUTS after the cancer treatment can significantly impair men's quality of life. While many men recover from LUTS spontaneously over time, a significant proportion require long‐term management. Despite the prevalence of LUTS, there is a lack of consensus on best management. This article offers a comprehensive treatment algorithm to manage patients with LUTS following pelvic cancer treatment.ConclusionBased on published research literature and clinical experience, recommendations are proposed for the standardisation of management strategies employed for men with LUTS after the pelvic cancer treatment. In addition to implementing the algorithm, understanding the rationale for the type and timing of LUTS management strategies is crucial for clinicians and patients.

show abstract

Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy–Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial

Cited by 41 publications

References 32 publications

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment

Urethral toxicity after LDR brachytherapy: Experience in Japan

Integrative review on the non‐invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies

Contact Info

Product

Resources

About